This activity will focus on the role of interleukin-17 (IL-17) inhibitors in the treatment of psoriatic arthritis (PsA) patients who showed an inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), review the updated treatment guidelines regarding initiation of IL-17 inhibitors, and discuss the clinical evidence to support IL-17 inhibitors.

Learning outcomes

By the end of this course, participants should be able to:

  • Outline the importance of IL-17 inhibitors in the treatment of PsA patients who are inadequately responding to csDMARDs
  • Discuss the recommendations from treatment guidelines regarding the initiation of IL-17 inhibitors
  • Summarise the efficacy and safety of IL-17 inhibitors
  • Discuss the benefits of initiating IL-17 inhibitors in biologic-naïve PsA patients.


This education has been designed for the RACP CPD Program for the 2023-25 triennium. Upon completion of this activity you may claim 1 hour of Category 1 Educational Activity learning in the RACP’s MyCPD program.

Other healthcare professionals can still enrol and complete this course. You will receive a certificate upon completion.


If you do not already have an account with Arterial Education, you will be required to create one. This verifies that you are a healthcare professional and allows you to log your learning activities.